Skip to content

Efficacy of Bushen Huatan Decoction on the treatment of Polycystic Ovarian Syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness

Efficacy of Bushen Huatan Decoction on the treatment of Polycystic Ovarian Syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053358
Enrollment
Unknown
Registered
2021-11-20
Start date
2022-03-01
Completion date
Unknown
Last updated
2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome

Interventions

Experimental group1:Kidney-Tonifying and Phlegm-Dispelling Prescription
Experimental group2:"Kidney-Tonifying and Phlegm-Dispelling Prescription" Combined with Metformin hydrochloride sustained-release tablets

Sponsors

Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 35 years, female; 2. Comply with Western Medicine Diagnostic Standard (IR-PCOS); 3. Comply with the standard of TCM syndrome differentiation and diagnosis; 4. No history of hormone drugs and drugs affecting glucose metabolism in the first 3 months of treatment; 5. Volunteer participation and informed consent.

Exclusion criteria

Exclusion criteria: 1. Combined with other endocrine disorders related to this disease (such as Cushing's syndrome, hyperprolactinemia, etc.); 2. Combined with congenital malformations or defects of the reproductive system, organic diseases of the reproductive system (such as uterine fibroids, ovarian cysts, etc.); 3. Combined with germline malignant tumors (such as endometrial cancer, cervical cancer, etc.); 4. Combined with genital inflammation, genital tuberculosis, pelvic inflammatory disease; 5. Either one of the husband and wife has sexually transmitted diseases such as syphilis and AIDS; 6. Combined with serious primary diseases of cardiovascular and cerebrovascular, liver, kidney and hematopoietic system and mental patients; 7. Combined with chromosomal abnormalities, or in pregnancy or lactation; 8. Allergic to the drugs used in this research.

Design outcomes

Primary

MeasureTime frame
Homeostatic model assessment of insulin resistance;Oral glucose tolerance test;Insulin release test;

Secondary

MeasureTime frame
Serum sex hormone;The menstrual cycle;The ovulation rate;Clinical pregnancy rate;Body mass index;Ferriman-Gallwey score;Rosenfield score;Traditional Chinese Medicine syndrome integral;Intestinal flora detection;Total transcriptome sequencing;

Countries

China

Contacts

Public ContactWang Lihong

Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine

wanglihong8008@163.com+86 15250358008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026